rethinkPeptides Search
Menu
Home / Research library
Study breakdown

The Substantia Nigra Is a Powerful Pain Control Center — But Only Through Mu Opioid Receptors

RPEP-001861991Baumeister, A A
Animal StudyPreliminary evidence
The takeaway

Mu opioid agonist injected into the substantia nigra produced pain relief comparable to the periaqueductal gray, while delta and kappa agonists were ineffective — identifying a new brain pain control site.

Mu-only pain control in substantia nigra

Only mu agonists produced antinociception in the substantia nigra, with potency comparable to the periaqueductal gray

What the researchers found

Mu-selective agonist DAGO injected into the substantia nigra produced antinociception comparable to the periaqueductal gray. Delta and kappa agonists had no effect.

Why it matters

This study identifies the substantia nigra as a key brain region for opioid pain control. Previously, most attention focused on the periaqueductal gray. Knowing that multiple brain areas contribute to pain relief could improve pain treatment strategies.

How the study worked

Rats received bilateral microinjections of selective opioid agonists into the substantia nigra. Pain was tested using tail-flick and hot-plate methods. Antagonists confirmed receptor specificity.

What this study cannot tell us

Animal study in rats using direct brain injections. This invasive method is not applicable to human treatment. The substantia nigra is primarily known for movement control, and effects on motor function could confound pain testing.

How to read the evidence

Preliminary animal study using direct brain microinjection. Demonstrates receptor specificity but invasive technique.

When this study was published

Published in 1991. The substantia nigra's role in pain processing has been further confirmed and is relevant to Parkinson's pain research.

The bigger picture

Identifying additional brain pain control centers expands our understanding of how the brain manages pain. The substantia nigra's dual role in movement and pain may explain why Parkinson's patients commonly experience both movement and pain problems.

Questions still open

  • Does the pain control function of the substantia nigra deteriorate in Parkinson's disease?
  • Could nigral mu receptor targeting provide a new approach to pain management?

Common questions

Why is finding a new pain control center important?
The more brain pain centers we identify, the more therapeutic targets we have. If conventional pain drugs target one center, knowing about others could lead to combination approaches or treatments for patients who don't respond to standard therapy.
How does this relate to Parkinson's disease?
The substantia nigra degenerates in Parkinson's. If this region also controls pain, its degeneration could explain why up to 80% of Parkinson's patients experience chronic pain — and why it often doesn't respond well to standard pain treatments.

Read the original research

The effects of bilateral intranigral microinjection of selective opioid agonists on behavioral responses to noxious thermal stimuli.

Brain research, 557(1-2), 136-45

View on PubMed ↗

Citation

Baumeister, A A. (1991). The effects of bilateral intranigral microinjection of selective opioid agonists on behavioral responses to noxious thermal stimuli.. Brain research, 557(1-2), 136-45.